European Medicines Agency validates submission of MAA for Nidlegy
Nidlegy is partnered with Sun Pharma for the treatment of Skin Cancers in Europe, New Zealand and Australia. Both companies jointly made the following announcements:
– 23 October 2023 – Phase III PIVOTAL trial met the primary endpoint
– 31 May 2024 – Primary results of PIVOTAL presented at ASCO
– 04 June 2024 – MAA submission to EMA
The data of the Phase III Nidlegy trial are expected to be published in a peer-reviewed scientific journal in 2024.
Powered by Capital Market – Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
First Published: Jul 04 2024 | 3:04 PM IST
Related
Securitas tops Q4 core profit expectations driven by European business
(Reuters) - Sweden's Securitas reported fourth quarter core profit above market expectations on Thursday, mainly driven by its security services business in
EC Competitiveness Compass introduces European business wallet | Biometric Update
The European Commission (EC) has launched its Competitiveness Compass, a scheme that aims to equip Europe to keep pace with worldwide trends in digita
ThredUp sells European business to focus on US
ThredUp Inc., a major online resale platform for apparel, shoes, and accessories, has sold its European subsidiary business, Remix, in a management-led
European and UK stock markets hit by global trade war…
European markets hit by trade war anxiety.European stock markets are a sea of red in early trading, after Donald Trump rattled investors by signing off on tarif
